covid-19 information vaccine

Emergent to produce drug substance for J&Js Covid-19 vaccine

Reading now: 400
www.pharmaceutical-technology.com

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Emergent BioSolutions has entered a five-year agreement with Johnson & Johnson unit Janssen Pharmaceutical for large-scale manufacturing of drug substance for the latter’s Covid-19 vaccine candidate, Ad26.COV2-S.

As part of the deal, Emergent agreed to offer contract development and manufacturing (CDMO) services for drug substance production, valued at about $480m for the initial two years.

The company will start delivering manufacturing services for the Ad26.COV2-S vaccine in 2021, after the activities covered by the previously executed technology transfer agreement are complete.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA